Substance Use Screening to Encourage Behavior Change Among Young People in Primary Care
Launched by PROF. DAGMAR M. HALLER · Oct 30, 2019
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether filling out a short questionnaire about substance use while waiting to see a doctor can help reduce excessive drinking and drug use among young people aged 14 to 24. When young patients come to a primary care clinic, they will randomly get either a questionnaire about their substance use or one about physical activity. Later, the researchers will check back with them at 3, 6, and 12 months to see if their substance use has changed. The goal is to find out if those who completed the substance use questionnaire are less likely to engage in excessive substance use compared to those who filled out the physical activity questionnaire.
To participate in this study, young people must be between 14 and 24 years old and visiting the primary care clinic for any reason. However, those with immediate health issues, serious mental health conditions, or who are not patients at the clinic cannot take part. Participants can expect to fill out a questionnaire during their visit and receive follow-up surveys later. This trial aims to improve health behaviors among young people, and it is an exciting opportunity to contribute to important research in a supportive environment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Patients aged 14 to 24 years consulting at the participating primary care practice for any motive.
- Exclusion Criteria:
- • Acute illness requiring immediate attention of the physician
- • Severe mental health conditions requiring treatment in a specialized setting
- • Young person not consulting as a patient at the practice (e.g. accompanying friend or partner)
- • Inability to read the trial information in French or to provide independent consent.
About Prof. Dagmar M. Haller
Prof. Dagmar M. Haller is a distinguished clinical trial sponsor known for her extensive expertise in medical research and a commitment to advancing healthcare through innovative clinical studies. With a robust background in clinical pharmacology and patient-centered research, she leads initiatives aimed at evaluating novel therapies and interventions. Prof. Haller is dedicated to fostering collaboration among multidisciplinary teams to ensure the highest standards of scientific rigor and ethical conduct in clinical trials. Her work not only contributes to the body of medical knowledge but also strives to improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Geneva, , Switzerland
Patients applied
Trial Officials
Dagmar M Haller, MD,PhD
Principal Investigator
Faculty of Medicine, University of Geneva
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials